Your browser doesn't support javascript.
loading
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Finn, Richard S; Kudo, Masatoshi; Cheng, Ann-Lii; Wyrwicz, Lucjan; Ngan, Roger K C; Blanc, Jean-Frederic; Baron, Ari D; Vogel, Arndt; Ikeda, Masafumi; Piscaglia, Fabio; Han, Kwang-Hyub; Qin, Shukui; Minoshima, Yukinori; Kanekiyo, Michio; Ren, Min; Dairiki, Ryo; Tamai, Toshiyuki; Dutcus, Corina E; Ikezawa, Hiroki; Funahashi, Yasuhiro; Evans, Thomas R Jeffry.
Afiliação
  • Finn RS; Division of Hematology/Oncology, Geffen School of Medicine, UCLA Medical Center, Santa Monica, California. rfinn@mednet.ucla.edu.
  • Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Cheng AL; National Taiwan University Cancer Center, Taipei, Taiwan.
  • Wyrwicz L; Centrum Onkologii-Instytut im., M. Sklodowskiej Curie, Warsaw, Poland.
  • Ngan RKC; Queen Elizabeth Hospital, Kowloon, Hong Kong.
  • Blanc JF; University Hospital of Bordeaux, Bordeaux, France.
  • Baron AD; California Pacific Medical Center, San Francisco, California.
  • Vogel A; Hannover Medical School, Hannover, Germany.
  • Ikeda M; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Piscaglia F; General and University Hospital S. Orsola-Malpighi, Bologna, Italy.
  • Han KH; Severance Hospital, Yonsei University, Seoul, South Korea.
  • Qin S; Nanjing Bayi Hospital, Nanjing, Jiangsu, China.
  • Minoshima Y; Eisai Co., Ltd., Tsukuba, Ibaraki, Japan.
  • Kanekiyo M; Eisai Inc., Woodcliff Lake, New Jersey.
  • Ren M; Eisai Inc., Woodcliff Lake, New Jersey.
  • Dairiki R; Eisai Co., Ltd., Tsukuba, Ibaraki, Japan.
  • Tamai T; Eisai Co., Ltd, Tokyo, Japan.
  • Dutcus CE; Eisai Inc., Woodcliff Lake, New Jersey.
  • Ikezawa H; Eisai Co., Ltd, Tokyo, Japan.
  • Funahashi Y; Eisai Co., Ltd., Tsukuba, Ibaraki, Japan.
  • Evans TRJ; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
Clin Cancer Res ; 27(17): 4848-4858, 2021 09 01.
Article em En | MEDLINE | ID: mdl-34108184
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Quinolinas / Biomarcadores Tumorais / Carcinoma Hepatocelular / Sorafenibe / Neoplasias Hepáticas / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Quinolinas / Biomarcadores Tumorais / Carcinoma Hepatocelular / Sorafenibe / Neoplasias Hepáticas / Antineoplásicos Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos